Clinical characteristics of AML patients and samples
| Target . | Forward primer . | Reverse primer . |
|---|---|---|
| Arginase I | 5′CTCTAAGGGACAGCCTCGAGGA3′ | 5′TGGGTTCACTTCCATGATATCTA3′ |
| Arginase II | 5′ATGTCCCTAAGGGGCAGCCTCTCGCGT3′ | 5′CACAGCTGTAGCCATCTGACACAGCTC3′ |
| iNOS | 5′CGGTGCTGTATTTCCTTACGAGGCGAAGAAGG3′ | 5′GGTGCTGCTTGTTAGGAGGTCAAGTAAAGGGC3′ |
| GAPDH | 5′CCAGCCGAGCCACATCGCTC3′ | 5′ATGAGCCCCAGCCTTCTC3′ |
| Target . | Forward primer . | Reverse primer . |
|---|---|---|
| Arginase I | 5′CTCTAAGGGACAGCCTCGAGGA3′ | 5′TGGGTTCACTTCCATGATATCTA3′ |
| Arginase II | 5′ATGTCCCTAAGGGGCAGCCTCTCGCGT3′ | 5′CACAGCTGTAGCCATCTGACACAGCTC3′ |
| iNOS | 5′CGGTGCTGTATTTCCTTACGAGGCGAAGAAGG3′ | 5′GGTGCTGCTTGTTAGGAGGTCAAGTAAAGGGC3′ |
| GAPDH | 5′CCAGCCGAGCCACATCGCTC3′ | 5′ATGAGCCCCAGCCTTCTC3′ |